Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection

The newly emerged SARS-CoV-2 caused a global pandemic with astonishing mortality and morbidity. The mechanisms underpinning its highly infectious nature remain poorly understood. We report here that SARS-CoV-2 exploits cellular CTP synthetase 1 (CTPS1) to promote CTP synthesis and suppress interferon (IFN) induction. Screening a SARS-CoV-2 expression library identified ORF7b and ORF8 that suppressed IFN induction via inducing the deamidation of interferon regulatory factor 3 (IRF3). Deamidated IRF3 fails to bind the promoters of classic IRF3-responsible genes, thus muting IFN induction. Conversely, a shRNA-mediated screen focused on cellular glutamine amidotransferases corroborated that CTPS1 deamidates IRF3 to inhibit IFN induction. Functionally, ORF7b and ORF8 activate CTPS1 to promote de novo CTP synthesis while shutting down IFN induction. De novo synthesis of small-molecule inhibitors of CTPS1 enabled CTP depletion and IFN induction in SARS-CoV-2 infection, thus impeding SARS-CoV-2 replication. Our work uncovers a strategy that a viral pathogen couples immune evasion to metabolic activation to fuel viral replication. Inhibition of the cellular CTPS1 offers an attractive means for developing antiviral therapy that would be resistant to SARS-CoV-2 mutation.

[1]  R. Hotchkiss,et al.  Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm , 2020, Science Advances.

[2]  N. Grandvaux,et al.  ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities , 2020, eLife.

[3]  J. Kos,et al.  The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors , 2020, PLoS pathogens.

[4]  Penghua Wang,et al.  Mechanisms of SARS-CoV-2 Transmission and Pathogenesis , 2020, Trends in Immunology.

[5]  Min Zheng,et al.  A systematic review of SARS-CoV-2 vaccine candidates , 2020, Signal Transduction and Targeted Therapy.

[6]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[7]  F. Krammer SARS-CoV-2 vaccines in development , 2020, Nature.

[8]  Vineet D. Menachery,et al.  Evasion of Type I Interferon by SARS-CoV-2 , 2020, Cell Reports.

[9]  J. Gamble,et al.  Animal and translational models of SARS-CoV-2 infection and COVID-19 , 2020, Mucosal Immunology.

[10]  L. Ren,et al.  Activation and evasion of type I interferon responses by SARS-CoV-2 , 2020, Nature Communications.

[11]  Zhenghao Xu,et al.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies , 2020, Frontiers in Immunology.

[12]  S. Nisole,et al.  Interplay between SARS-CoV-2 and the type I interferon response , 2020, PLoS pathogens.

[13]  J. Ayres,et al.  A metabolic handbook for the COVID-19 pandemic , 2020, Nature metabolism.

[14]  Rui Luo,et al.  The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway , 2020, Virus Research.

[15]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[16]  S. Cascarina,et al.  A proposed role for the SARS‐CoV‐2 nucleocapsid protein in the formation and regulation of biomolecular condensates , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  R. Bruno,et al.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[18]  Akiko Iwasaki,et al.  Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19 , 2020, Cell Host & Microbe.

[19]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[20]  M. Rotondi,et al.  The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system , 2020, Cytokine & Growth Factor Reviews.

[21]  S. Ghafari,et al.  Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections , 2020, Future Virology.

[22]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[23]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[24]  Marcus J Schultz,et al.  Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings , 2020, The American journal of tropical medicine and hygiene.

[25]  Wenjie Zhu,et al.  Deamidation Shunts RelA from Mediating Inflammation to Aerobic Glycolysis. , 2020, Cell metabolism.

[26]  L. Prokunina-Olsson,et al.  Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019 , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[27]  C. Chiang Faculty Opinions recommendation of SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[28]  K. Yuen,et al.  Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.

[29]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[30]  Jun Zhao,et al.  Antiviral activity of a purine synthesis enzyme reveals a key role of deamidation in regulating protein nuclear import , 2019, Science Advances.

[31]  M. Kikkert,et al.  Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections , 2019, Viruses.

[32]  G. Zlabinger,et al.  Hijacking the Supplies: Metabolism as a Novel Facet of Virus-Host Interaction , 2019, Front. Immunol..

[33]  C. Thompson,et al.  Metabolic regulation of cell growth and proliferation , 2019, Nature Reviews Molecular Cell Biology.

[34]  W. Eisenreich,et al.  How Viral and Intracellular Bacterial Pathogens Reprogram the Metabolism of Host Cells to Allow Their Intracellular Replication , 2019, Front. Cell. Infect. Microbiol..

[35]  G. Amarante-Mendes,et al.  Pattern Recognition Receptors and the Host Cell Death Molecular Machinery , 2018, Front. Immunol..

[36]  Lin Chen,et al.  Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral Replication. , 2018, Cell host & microbe.

[37]  Trevor Siggers,et al.  DNA-binding landscape of IRF3, IRF5 and IRF7 dimers: implications for dimer-specific gene regulation , 2018, Nucleic acids research.

[38]  J. Estaquier,et al.  Viral Manipulation of the Host Metabolic Network. , 2018, Experientia supplementum.

[39]  Ji-Long Liu,et al.  Critical roles of CTP synthase N-terminal in cytoophidium assembly , 2017, Experimental cell research.

[40]  Rob Phillips,et al.  Energetic cost of building a virus , 2017, Proceedings of the National Academy of Sciences.

[41]  Jian Peng,et al.  A Viral Deamidase Targets the Helicase Domain of RIG-I to Block RNA-Induced Activation. , 2016, Cell host & microbe.

[42]  Jun Zhao,et al.  Emerging Roles of Protein Deamidation in Innate Immune Signaling , 2016, Journal of Virology.

[43]  W. A. van der Donk,et al.  The many roles of glutamate in metabolism , 2016, Journal of Industrial Microbiology & Biotechnology.

[44]  M. Lagunoff,et al.  Viral activation of cellular metabolism. , 2015, Virology.

[45]  E. Zandi,et al.  Viral pseudo-enzymes activate RIG-I via deamidation to evade cytokine production. , 2015, Molecular cell.

[46]  Youliang Rao,et al.  Dynamic localization and the associated translocation mechanism of HMGBs in response to GCRV challenge in CIK cells , 2014, Cellular and Molecular Immunology.

[47]  A. Fischer,et al.  CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation , 2014, Nature.

[48]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[49]  C. Risco,et al.  Virus factories: biogenesis and structural design , 2012, Cellular microbiology.

[50]  L. Graves,et al.  Regulation of Human Cytidine Triphosphate Synthetase 2 by Phosphorylation* , 2010, The Journal of Biological Chemistry.

[51]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[52]  T. Mogensen Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses , 2009, Clinical Microbiology Reviews.

[53]  G. Carman,et al.  Phosphorylation of human CTP synthetase 1 by protein kinase A : Identification of Thr455 as a major site of phosphorylation , 2007 .

[54]  R. Medzhitov,et al.  Type I interferons in host defense. , 2006, Immunity.

[55]  I. Miyahara,et al.  Crystal structures of CTP synthetase reveal ATP, UTP, and glutamine binding sites. , 2004, Structure.

[56]  M. Badet-Denisot,et al.  The mechanism of glutamine-dependent amidotransferases , 1998, Cellular and Molecular Life Sciences CMLS.